Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Combination immunotherapy in RCC

05-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Updated KEYNOTE-426 data

Elizabeth Plimack presents the 2-year update of the KEYNOTE-426 study pitting the combination of pembrolizumab plus axitinib against sunitinib for treatment-naïve advanced renal cell carcinoma (1:45).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The FRACTION-RCC study

Toni Choueiri reports preliminary results from the FRACTION-RCC study showing encouraging efficacy of nivolumab plus ipilimumab in advanced renal cell carcinoma patients who have progressed on prior immunotherapy (3:11).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Perioperative durvalumab for locally advanced RCC

Moshe Ornstein reports on a phase 1b trial of perioperative durvalumab alone or alongside tremelimumab for the treatment of locally advanced renal cell carcinoma (5:17).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The RADVAX RCC study

Hans Hammers discusses the RADVAX RCC trial combining dual checkpoint blockade and stereotactic body radiotherapy for the treatment of metastatic renal cell carcinoma, and also comments on the similar NIVES study (2:16).

Read the accompanying news story

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

01-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: JAVELIN Renal 101 – combination approach for advanced RCC patients without upfront cytoreductive nephrectomy

Laurence Albiges discusses a JAVELIN Renal 101 subgroup analysis indicating that avelumab plus axitinib achieves tumor reduction in patients with metastatic renal cell carcinoma (2:30).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

30-09-2019 | Renal cell carcinoma | Video | Article

Researcher comment: TITAN-RCC findings show efficacy of tailored immunotherapy approach

Marc-Oliver Grimm talks through the results of the tailored nivolumab plus boost ipilimumab approach used in the TITAN-RCC study (3:38).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Image Credits